

1 **TITLE PAGE**

2 **Title:** Temporal dynamics of skin microbiota and immune correlates in psoriasis patients

3 receiving systemic treatment

4 **Running title:** Microbiota, treatment, and responses in psoriasis

5 **Authors:** Su-Hsun Liu,^{a,b} Yu-Huei Huang,^{c,d} Hao-Jui Weng,^{e,f,g} Tsen-Fang Tsai,^{e,h} Huang-Yu

6 Yang,^{c,i} Leslie Y Chen,^j Yen-Ling Chiu,^k Hsiao-Yun Yu,^c Yi-Chieh Chiu,^b Chao-Yu Ng,^{c,d} Ya-

7 Ching Chang,^d Chung-Yee R Hui,^d Yhu-Chering Huang^l

8 **Affiliations:**

9 a. International Health Program, National Yang Ming University, Taipei, Taiwan

10 b. Health Management Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan

11 c. College of Medicine, Chang Gung University, Taoyuan City, Taiwan

12 d. Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

13 e. Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan

14 f. Department of Dermatology, School of Medicine, College of Medicine, Taipei Medical

15 University, Taipei, Taiwan

16 g. Department of Dermatology, Taipei Medical University- Shuang Ho Hospital, New Taipei

17 city, Taiwan

18 h. Department of Dermatology, School of Medicine, College of Medicine, National Taiwan

19 University, Taipei, Taiwan

20 i. Department of Nephrology, Chang Gung Memorial Hospital, Taoyuan, Taiwan

21 j. Department of Medical Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

22 k. Department of Nephrology, Far Eastern Memorial Hospital, New Taipei City, Taiwan

23 l. Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan

24 **Correspondence author:** Su-Hsun Liu, MD MPH PhD

25 Current affiliation: Department of Ophthalmology, University of Colorado Anschutz Medical

26 Campus, Aurora CO, USA

27 Email: suhsun.liu@cuanschutz.edu

28

29 **Funding sources:** The current study was supported by Ministry of Science and Technology,

30 Taiwan [MOST 104-2314-B-182-002, 105-2628-B-182-006, 107-2314-B-418-015 to S Liu];

31 Chang Gung Medical Foundation [CMRPG3E1971-72 and BMRPE29 to S Liu]; Far Eastern

32 Memorial Hospital [FMRP107-2314B418015 to S Liu]. The funders had no role in preparing or

33 submitting the current work.

34

35 **Keywords:** Skin microbiota (Microbiology), psoriasis, clinical outcomes, epidemiology (Cohort

36 study), biomarkers, systemic treatment

37

38 **Manuscript word count:** abstract 284 (300); text 3077 (3000)

39

40 **Figures and tables:** 2 figures and 4 tables

41 **ABSTRACT**

42 **Background**

43 How skin microbiota in psoriasis patients responded to systematic therapeutics remained
44 unknown.

45 **Objectives**

46 To profile temporal shifts in transcriptionally active skin microbiota in psoriasis patients
47 receiving systemic therapies.

48 **Methods**

49 We prospectively enrolled 61 psoriasis patients and 29 skin-healthy controls in 2015-2019.
50 Using RNA-based 16S rRNA gene sequencing, we analyzed 969 samples from skin lesions
51 and compared microbial abundance and diversity by therapeutic classes and disease severity.

52 **Results**

53 Lesional microbiota in patients on conventional systemics and TNF- α inhibitor was different
54 in relative abundances in Firmicutes (7.83% higher, adjusted $P < 0.001$) and Proteobacteria
55 (6.98% lower, adjusted $P < 0.01$) from that in patients on anti-interleukin monoclonal
56 antibodies (anti-ILAb) at baseline. The only difference during treatment was a 1.47% lower
57 abundance in *Bacteroides* associated with nonbiologics use (adjusted $P < 0.01$). We
58 identified no indicator taxa by disease severity at baseline yet noticed that a minor relative
59 reduction in *Corynebacterium* sp. was associated with clinical responses to treatment.

60 Compared to anti-ILAb, TNF- α inhibitor and nonbiologics were associated with -0.21 lower
61 Shannon Diversity (adjusted $P < 0.01$) and 0.03 higher Shannon Evenness (adjusted $P <$
62 0.01). Results of ordinated principal coordinates analysis revealed that, lesional microbiota
63 from patients of these 3 therapeutic groups was compositionally distinct. Our work also

64 demonstrated concurrent changes in clonal shifts in systemic T cell receptor clonotypes that
65 were associated with systemic use of biologics.

66 **Conclusions**

67 Community abundances and diversities of skin microbiota may be useful in distinguishing
68 skin microbiota from patients receiving different systemic therapeutics. Specifically, use of
69 anti-ILAb and TNF- α inhibitor was associated with sample-wise microbial abundances and
70 diversities, but not richness, over time. These findings highlighted the potential utility of skin
71 microbiota as biomarkers for personalized treatment plans in patients with moderate-to-
72 severe psoriasis.

73 INTRODUCTION

74 Psoriasis vulgaris (psoriasis) is a chronic immune disease that manifests as well-defined
75 scaly skin plaques, which may be associated with arthritis and systemic comorbidities [1].
76 Both innate immunity and T-cell response contribute to the disease pathogenesis,
77 constituting major therapeutic targets for effective systemic therapies [2]. Recently, skin
78 microbiota has emerged as novel candidate biomarkers for disease management [3, 4].
79 Despite the proven clinical effectiveness of anti-psoriatic therapies, few studies have
80 examined therapy-specific influences on lesional microbiota longitudinally [5]. A recently-
81 updated Cochrane review showed that biologics, including TNF- α inhibitor and anti-ILAb,
82 were more effective in achieving clinical remission as measured by PASI 90 (90% reduction
83 in Psoriasis Area and Severity Index relative to the baseline) than the small molecules and
84 conventional systemics in the trial setting [2]. However, whether and how conventional
85 therapies, TNF- α inhibitor, and anti-ILAb differentially alter the host microbiota in a non-
86 trial setting remains unstudied. Besides, whether clinical responses were associated with any
87 shifts in lesional microbiota has not been well-characterized [3]. As such, we sought to
88 delineate relationships among systemic therapies, treatment responses, and characteristics of
89 lesional microbiota in psoriasis patients via serial sampling. Particularly, to reduce
90 environmental influences on the low biomass of skin samples [6] and to provide an in-depth
91 insight into the relevant responses to a newly-prescribed regimens [7, 8], we sought to
92 profile transcriptionally-active skin microbiota using bacterial 16S rRNA transcript
93 sequencing. We also explored temporal changes in T cell receptor (TCR) repertoire diversity
94 during treatment for a better understanding of treatment effects on the host immunity.
95

96 **MATERIALS AND METHODS**

97 *Subject enrollment*

98 Between May 2015 and November 2019, we enrolled and followed adults (aged 20 years or
99 older) with psoriasis at Dermatology Outpatient Clinics of two tertiary hospitals (Chang Gung
100 Memorial Hospital and National Taiwan University Hospital) in Taiwan. Patients were eligible
101 for study entry when initiating new systemic therapy; majority of the washout period was > 4
102 weeks. We excluded those with a recent exposure to topical or systemic antibiotics,
103 immunosuppressants, or chemotherapies within 12 weeks prior to study enrollment. In 2016-
104 2019, we also recruited skin-healthy adults who did not have diagnoses of chronic inflammatory
105 skin disorders but either visited the same clinics for mole excision or alopecia treatment, or were
106 care givers of the index patients. Center-specific Institution Review Boards reviewed and
107 approved the study protocols, separately (CGMH 103-6837B, 104-9746B, 201702308B0C501;
108 NTUH 201809061RINB).

109

110 *Data and sample collection*

111 After obtaining written informed consent, well-trained research assistants conducted in-person
112 interviews to collect sociodemographic information, medical history, and behavioral habits.
113 Patients also reported quality of life and anxiety/depressive symptoms using Dermatology Life
114 Quality Index (DLQI)[9] questionnaire and Center for Epidemiologic Studies Depression Scale
115 (CESD-S)[10] at baseline and follow-up visits. According to European S3-Guidelines [11], we
116 grouped patients by non-biologics (acitretin, cyclosporin, methotrexate); anti-interleukin
117 monoclonal antibodies (anti-ILAb: ustekinumab, secukinumab, ixekizumab, and guselkumab);

118 tumor necrosis factor- α antagonists (TNF- α inhibitor: adalimumab, golimumab, and etanercept).
119 Treatment responses were absolute PASI scores and PASI 75 responses.

120

121 To profile skin microbiota from sequencing 16S rRNA gene transcripts, we used Tween20-
122 moistened FLOQSwabs (Copan, Murrieta, CA, USA) to collect scrapes over an area of 2 x 2 cm²
123 on pre-specified surfaces with active lesions [12, 13], including bilateral scalp, post-auricular
124 hairlines, extensor forearms, pretibial shafts, and palms; these sampling sites also applied to skin-
125 healthy controls. To facilitate swab collection, we requested the study participants to refrain from
126 bathing or body scrubbing at least 24 hours prior to a study visit. We also encouraged each
127 participant to cover up sampling sites with cotton-made clothing to reduce environmental
128 influences while in the study.

129

130 *16S rRNA gene transcript isolation, amplification, sequencing, and processing*

131 We performed RNA isolation by firstly disrupting bacterial cell walls in a chemical lysis buffer
132 [7]. Reverse transcription of total RNA immediately followed the recovery of RNA samples
133 using the SuperScript RT-PCR kit (Invitrogen, Carlsbad, CA, USA) according to the
134 manufacturer's manual. For each PCR sample, we confirmed the presence of amplicons by gel
135 electrophoresis. We included 2-3 negative controls for each library preparation as suggested in
136 the literature [14, 15], and mock community DNA (Zymo Research, Irvine, CA, USA) as
137 positive controls [16].

138

139 We applied 'mothur' (version 1.43.0) to the raw sequence reads using a modified reference
140 region for sequence alignment [17, 18] and clustered the filtered reads into operational taxonomy

141 units (OTU) at 97% identify before subsequent statistical analysis and graphing in R (v 4.0.2)
142 [19]. Using R packages ‘decontam’ and ‘phyloseq’ [15, 20], we identified and removed potential
143 contaminant taxa inferred from 63 negative control samples [21], singletons, and samples with
144 low coverage (< 400 reads/ sample). In total, we included 969 samples (82.0% of sequenced
145 samples) with a median of 43 577 reads per sample (interquartile range [IQR]: 33 987-55 972) in
146 the following analysis.

147

148 *TCR repertoire profiling*

149 We collected peripheral blood samples in EDTA tubes from 9 anti-ILAb users before and 12
150 weeks after treatment began. We also collected 1 blood sample from 7 skin-healthy participant at
151 baseline. Using flow cytometry, we sorted CD3+ T cells, from which RNA isolation was
152 performed by employing RNeasy Mini Kit (Qiagen). Procedures of the library preparation
153 included nested amplifications targeting the V-C regions of the complementarity-determining
154 region (CDR3) of TCR using TCR $\alpha\beta$ kits (iRepertoire, Huntsville, AL, USA).

155

156 *Statistical Analysis*

157 ***Patient data.*** We described and compared baseline participants’ characteristics by disease status
158 and therapy class (patients only) using median tests for independent continuous variables and
159 Chi-squared or Fisher’s exact test for categorical ones. We tested our hypothesis using
160 multivariable quantile regression analysis with robust or bootstrapped (3 000 replicates) variance
161 estimation to account for repeated measures. All longitudinal data analysis considered
162 observations over the 12-15 weeks of follow-up period to allow for sufficient statistical power.

163 We used Stata-MP (Version 13.1) with a 2-tailed significance of 0.01 for comparative analysis
164 [22], and employed R packages ‘ggplot2’ and ‘vegan’ for graphics production [23, 24].

165
166 **Microbiota data.** We calculated α -diversity measures of richness (observed number of unique
167 OTUs, Chao1 index), Shannon diversity (ShannonD) and Shannon evenness (ShannonE) indices
168 for quantifying within-sample variation. Based on non-metric and linear R^2 values, we chose
169 Bray-Curtis dissimilarity index to compare between-sample distance matrices [25]. We
170 performed hypothesis testing via permutational multivariate analysis of variance
171 (PERMANOVA, 10 000 permutations) [26]. We also repeated relevant analysis using read-based
172 rarefied datasets; the results did not alter our conclusions.

173
174 **TCR profiling.** We performed descriptive analysis by sample and patient characteristics;
175 compared differences in the normalized usage of V- and J-segment of the CDR3 gene, and in
176 diversity metrics of CDR3 clonotypes using bootstrapped quantile regression models to estimate
177 the empirical variance (3 000 replicates) in Stata-MP (Version 13.1) [22]. We applied a 2-tailed
178 significance level of 0.05 for exploratory analysis on gene expression and TCR sequence data.

179

180 **Data Availability**

181 We have deposited raw sequences of 16S rRNA transcripts and TCR transcripts to the Short
182 Read Archive (SRA) database under the BioProject accession number [PRJNA662768](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA662768).

183

184 **RESULTS**

185 **Study population**

186 We prospectively enrolled and followed 119 participants for 12 weeks or longer between 2015
187 and 2019. Ten patients received an extended observation for additional 6 months while receiving
188 maintenance biologics therapy (Fig. S1). We included 743 and 226 quality swabs from 61
189 psoriasis patients and 29 controls who returned at least once within 16 weeks in the current
190 analysis (follow-up rate: 87% and 83%). The patient population comprised mainly of men (87%)
191 (median age: 43 years) with an average disease duration of 23 years (IQR: 19-33). There were no
192 statistical differences in patient characteristics associated with therapeutic classes at study entry.
193 In total, 79% of patients had moderate-to-severe psoriasis; all patients of the 3 therapeutic groups
194 began with comparable disease severity at study entry (Table 1). Patients excluded based on low-
195 quality sequencing samples (N=5) were comparable to those included in the current analysis
196 (Table S1).

197
198 At 12-15 weeks after treatment began, disease activity in all patients declined significantly, with
199 the median PASI score decreasing from 15 (IQR: 11-20) to 4 (IQR: 1-8) (adjusted P for trend <
200 0.001). Patients in each therapeutic class had comparable trends in disease activities over time;
201 there were no significant differential group effects (all P for interaction tests > 0.01). Self-
202 reported DLQI also decreased substantially from 9 (IQR: 4-15) at baseline to 2 (0-8, adjusted P
203 for trend < 0.001) whereas self-reported anxiety symptoms as quantified by CESD scores did not
204 vary over time (Table S2).

205
206 **Normal versus lesional microbiota**
207 ***Microbial abundances.*** At study entry, phylum abundances in normal skin microbiota were
208 statistically comparable to those in lesional microbiota with or without accounting for

209 participants' age, sex, absence of prior treatment, and year of enrollment (Table 2). A relative
210 dominance of Proteobacteria in lesional microbiota by 3.35% (95%CI: 1.44%, 5.25%) emerged
211 over time (adjusted $P < 0.001$); simultaneous comparisons across disease status and sampling
212 sites revealed similar results (adjusted $P=0.002$, Fig. S2a). Likewise, we examined abundances of
213 the most common 6 genera as suggested in the literature [27] (Fig. S2b), and found no evidence
214 for indicator taxa between lesional and normal skin (Table S3).

215

216 Despite an over-representation of men in the patient group, results of sex-specific comparisons
217 between lesional and normal microbiota were alike at baseline but not longitudinally, during
218 which a relative over-abundance of Proteobacteria was significant in samples from male patients
219 by 4.13% (95%CI: 1.88%, 6.38%) as compared to normal skin (Table 2). Formal tests for disease
220 status-by-sex interaction were nonsignificant. Additional stratified analysis by the absence of
221 prior treatment found no significant subgroup effects either.

222

223 ***Microbial alpha- & beta-diversity.*** When compared to healthy skin, psoriatic lesions had
224 resembling microbial richness and diversity before and during treatment; only the degree of
225 community evenness (all unique taxa showing equal abundances) was lower in lesional than
226 normal microbiota (adjusted $P=0.01$; Table S4). Correspondingly, results of Bray-Curtis
227 distance-based PCoA showed an overall community similarity between the two groups
228 (PERMANOVA $P > 0.05$, Fig. S2c).

229

230 **Lesional microbiota, clinical treatment, and responses**

231 **Microbial abundances.** Before initiating new therapies, lesional microbiota of patients using
232 non-biologics had 7.83% more Firmicutes (95%CI: 4.26%, 10.5%) than those using anti-ILAb
233 (adjusted $P < 0.001$) whereas TNF- α inhibitor was associated with a 6.98% lower abundance
234 (95%CI: -12.2%, -1.73%) in Proteobacteria than anti-ILAb (Table 3). Over time, psoriatic
235 lesions in non-biologics users showed a relative 1.47% reduction (95%CI: -2.49%, -0.45%) in
236 Bacteroidetes as compared to anti-ILAb users while losing the dominance of Firmicutes
237 (adjusted $P > 0.01$, Fig. S3). Abundances in the four major phyla did not differ by initial disease
238 severity or patients' clinical responses as indicated by PASI 75 at follow-up (Table 3).
239
240 Stratified analysis by prior treatment history revealed a higher abundance of Firmicutes in
241 nonbiologics-associated samples from patients with previous treatment history (6.93%, 95%CI:
242 5.84%, 8.02%) but a lack thereof in those who were treatment-naïve. Similarly, subgroup
243 analysis by sex showed a significant reduction in Proteobacteria (-17.5%, 95%CI: -29.0%, -6.1%)
244 in women using TNF- α inhibitor as compared to anti-ILAb but no statistical differences by
245 therapy group in men.
246
247 At genus levels, *Staphylococcus* sp. was more abundant in samples from the non-biologics group
248 than the anti-ILAb group (adjusted $P < 0.001$) at baseline. There were no significant differential
249 abundances by baseline disease severity (PASI > 10). Longitudinally, classes of systemic
250 therapies were not associated with any indicator genera considered. Instead, lesions of PASI 75
251 responders had a 0.38% decrease in *Corynebacterium* sp. but nonsignificant differences in other
252 genera relative to poor responders (Table S5).
253

254 **Microbial alpha- & beta-diversity.** Before treatment began, α -diversity measures of skin
255 microbiota appeared comparable among samples from the three therapeutic groups, or by initial
256 degrees of disease severity (Table 4). During the follow-up period, we noted a significant
257 decrease (-0.21; 95%CI: -0.37, -0.06) and increase (0.03; 95%CI: 0.01, 0.06) in Shannon D and
258 Shannon E of the TNF- α inhibitor group and the non-biologics group relative to the reference
259 group, separately (Fig. 1a). Results of distance-based analysis of variance suggested significant
260 pair-wise dissimilarities between samples from healthy skin microbiota and lesional microbiota
261 of patients receiving anti-ILAb or TNF- α inhibitor (both permuted $P < 0.001$, Fig. 1b). On the
262 other hand, samples from non-biologics users and healthy controls were compositionally similar
263 as shown in unconstrained PCoA (Fig. S4a). Again, sample-wise α -diversity measures in PASI
264 75 responders and poor responders were indistinguishable during treatment (Table 4), wherefore
265 these results were compatible to results of β -diversity analysis (Fig. S4b).

266

267 **Clonal shifts of TCR during treatment**

268 In TCR analysis, we included sequencing results of 8 samples with 4157 (amino acid sequence)
269 unique CDR3 clonotypes (IQR: 2282 - 5642) identified per sample. The average D50 value was
270 2.8% (IQR: 2.1%-3.2%), suggesting that the most abundant 131 clonotypes accounted for 50%
271 of the total sample reads; there were no statistical differences in D50 values by disease status at
272 baseline (median difference: 0.9%, 95%CI: -4.5%, 6.3%). Shannon Diversity index of TCR
273 repertoire in psoriasis patients varied little after treatment (Table S6). We also showed that,
274 among 10 out of 13 J- and 48 V-segment genes, treatment-associated changes were significant
275 for segment hTRBJ1-6 (+0.9%, 95%CI: 0.4%, 1.4%), hTRBJ2-6 (+1.4%, 95%CI: 0.3%, 2.5%),

276 and hTRBV3-1 (-0.7%, 95% CI: -1.4%, -0.03%) in after- versus before-treatment comparisons
277 among psoriasis patients (Fig. 2).

278

279 **DISCUSSION**

280 In this prospective cohort study, we showed that, transcriptionally-active skin microbiota in
281 psoriasis patients of 3 major therapeutic classes displayed distinctive community abundances and
282 diversities before and after treatment. Over the past decade, the well-debated observations that
283 TNF- α inhibitor could increase patients' risks for severe infections [28, 29], such as reactivation
284 of latent tuberculosis [30, 31], and the less-debated low risks of similar adverse events in patients
285 receiving IL-17A or IL-12/23p40 inhibitor [32, 33], have led to our hypothesized differential
286 effects of systemic therapies on lesional microbiota. Since both biologics lead to a common,
287 downregulated secretion of cytokines, chemokines, and AMPs, such β -defensins and S100
288 proteins [12], we anticipated starker contrasts between lesional microbiota in biologics and
289 nonbiologics users than between samples from patients receiving different biologics. The
290 observation that only results of β -analysis conformed with our conjectures, alluded the multi-
291 dimensional complexity in quantifying (dis)similarities among groups of surveyed human
292 microbiota [21].

293

294 Besides specific immune perturbations inflicted on lesional microbiota by different therapies, the
295 initial community structure may partially account for the group differences observed
296 longitudinally. For instance, non-biologics users had the highest relative abundance of
297 Firmicutes (25.8%, IQR: 22.1%, 29.4%) at baseline (anti-ILAb: 20.3%; TNF- α inhibitor: 21.8%),
298 yet their lesional microbiota also followed a significant decline temporally (in Firmicutes, -

299 0.06% per day, 95% CI: -0.09%, -0.02%). Rates of changes in the other 2 treatment groups
300 remained nonsignificant, leading to a consensus post-treatment state across the comparison
301 groups. Contrary to the other two groups, samples from anti-ILAb patients showed evident
302 stability in community abundances, richness, and diversity over the treatment period, rendering
303 the group as an optimal reference for within-patient comparisons.

304

305 Our findings that the relative ranking in normalized usage of TCR segments TRBV3-1, V9, and
306 V11-2 examined in the current study, agreed with an early investigation by Tsuda et al. in
307 evaluating effects of ustekinumab on the presence or absence of TRB V-segments in psoriasis
308 patients [34]. These transcriptional shifts in selective CDR3 clonotypes (31% of 13 J-segments,
309 13% of 48 V-segments) of circulating T cells in patients receiving IL-12/-23 or IL-17A
310 monoclonal antibodies suggested host systemic responses in T cell differentiation after 12-week
311 exposure to blockade against the Th1/Th17 axis. Whether these transitions in TCR clonality
312 resulted from direct depletion of associated lineages or indirect responses to a re-shaping of skin
313 microbiota, was beyond the study's scope.

314

315 Conversely, the notion that characteristics of lesional microbiota were not linked to pre-treatment
316 disease severity, was contrary to a previously-reported negative correlation found between
317 baseline absolute PASI score and Shannon Diversity. In a pre-post study on effects of UVB
318 treatment, Assarsson and colleagues found that there were no similarly positive relationships
319 between disease severity and microbial diversity after treatment [35]. Although *Corynebacterium*
320 sp. has been implicated in IL-1 β production and expansion of $\gamma\delta$ T₁₇ cells in inflammatory skin
321 conditions of model animals [36], our finding that a minor decrease in *Corynebacterium* sp. was

322 associated with clinical responses during treatment, warrants additional research to confirm its
323 potential clinical utility.

324

325 Although the observation that normal skin harbored fewer Proteobacteria than lesional
326 microbiota, was inconsistent with previous findings [13, 37], such cross-study inconsistency has
327 been well-recognized in the literature [27]. Potential sources of disagreements may include
328 heterogeneous patient characteristics under different investigations; choices of analytic
329 approaches; intrinsic discrepancies in DNA- vs. RNA-based profiling of bacterial 16S rRNA
330 genes of skin microbiota. Particularly, Belheouane and others compared the murine ear skin
331 microbiota of standing and active microbial communities using 16S rRNA genes and transcripts
332 sequence data, respectively, and concluded that, RNA- was better than DNA-based profiling in
333 reducing environmental contaminations [6]. Given that comparisons in microbial abundances
334 and α diversity measures between DNA- and RNA-based methods may not always agree with
335 each other even within the same study [8, 14, 38, 39], between-study heterogeneities can be
336 expected; nonetheless, comparative results obtained by either technique shall remain valid within
337 each study [14].

338

339 **Limitations**

340 A few limitations are noteworthy in the current analysis. First, as an observational study, we did
341 not specify group sizes for each treatment group *a priori*; restrictions on funding also precluded
342 extended recruitment. The impacts of unequal group sizes and the broad-ranging grouping of
343 patients receiving conventional systemics or anti-ILAb, were uncertainties and possibly
344 attenuated associations. As such, results of comparisons by therapeutic class required careful

345 interpretation and generalization. According to a population-based patient registry in Sweden,
346 female patients generally had a lower PASI score than male patients across the age groups [40].
347 Since the current study sought to enroll patients with moderate-to-severe psoriasis, the
348 predominance of men in our patient population was expected and the sex-adjusted comparison
349 results within the patient population remained relevant and valid, particularly to those receiving
350 systemic treatment. Although proportions of patients receiving different systemic therapeutics
351 did not differ substantially across the recruitment waves, microbial structure, and diversity of
352 lesional microbiota may be conditioned by patients' prior treatment, of which we used a proxy
353 variable (the absence of prior treatment) for statistical adjustment; the reported associations were
354 indeed weighted averages of a heterogeneous patient population. Lastly, we recognized the
355 challenges of low biomass even on skin lesions and attempted to sequence cDNA sequences of
356 16S amplicons instead of the corresponding DNA sequences directly. How this unique approach
357 could have resulted in biased representations of certain Phyla has not been well characterized
358 [41]. Future studies that collect detailed information on serial medications, may provide novel
359 insights on the long-term trajectories of therapeutic effects on the lesional microbiota.

360

361 **CONCLUSIONS**

362 The current study showed that, classes of systemic therapies were independently associated with
363 characteristics of lesional microbiota in adult psoriasis patients enrolled in a non-trial setting.
364 These findings may support for the clinical utility of transcriptionally-active skin microbiota as
365 biomarkers for tailoring systemic therapies to patients with moderate to severe psoriasis in
366 addition to the absolute PASI scores.

367 **CONFLICTS OF INTEREST**

368 The authors declared no conflicts of interests.

369

370 **FUNDING SOURCES**

371 The study was supported by Ministry of Science and Technology, Taiwan [MOST 104-2314-B-

372 182-002, 105-2628-B-182-006, 107-2314-B-418-015 to S Liu]; Chang Gung Medical

373 Foundation [CMRPG3E1971-72 and BMRPE29 to S Liu]; Far Eastern Memorial Hospital

374 [FMRP107-2314B418015 to S Liu]. The funders had no role in preparing or submitting the

375 current work.

376

377 **AUTHOR CONTRIBUTIONS**

378 Dr. S Liu had full access to all the data in the study and takes responsibility for the integrity of

379 the data and accuracy of the reported findings.

380 *Concept and design:* S Liu, YH Huang, T Tsai

381 *Acquisition, analysis, and interpretation of data:* S Liu, YH Huang, H Weng, T Tsai, H Yu, YC

382 Chiu

383 *Drafting of the manuscript:* S Liu, H Weng

384 *Critical revision of the manuscript for important intellectual content:* S Liu, H Weng, T Tsai,

385 YH Huang

386 *Statistical analysis:* S Liu

387 *Administrative, technical, or material support:* HY Yang, L Chen, YL Chiu, HY Yu, YC Chiu,

388 C Ng, Y Chang, C Hui, YC Huang

389 *Supervision:* S Liu

REFERENCES

- [1] Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. *JAMA : the journal of the American Medical Association*. 2020;323; 1945-1960.
- [2] Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane database of systematic reviews (Online)*. 2020;1; Cd011535.
- [3] Niemeyer-van der Kolk T, van der Wall HEC, Balmforth C, Van Doorn MBA, Rissmann R. A systematic literature review of the human skin microbiome as biomarker for dermatological drug development. *Br J Clin Pharmacol*. 2018;84; 2178-2193.
- [4] Harkins CP, Kong HH, Segre JA. Manipulating the Human Microbiome to Manage Disease. *JAMA : the journal of the American Medical Association*. 2019.
- [5] Loesche MA, Farahi K, Capone K, Fakharzadeh S, Blauvelt A, Duffin KC, et al. Longitudinal Study of the Psoriasis-Associated Skin Microbiome during Therapy with Ustekinumab in a Randomized Phase 3b Clinical Trial. *The Journal of investigative dermatology*. 2018;138; 1973-1981.
- [6] Belheouane M, Vallier M, Čepić A, Chung CJ, Ibrahim S, Baines JF. Assessing similarities and disparities in the skin microbiota between wild and laboratory populations of house mice. *The ISME journal*. 2020.
- [7] Yuan S, Cohen DB, Ravel J, Abdo Z, Forney LJ. Evaluation of methods for the extraction and purification of DNA from the human microbiome. *PloS one*. 2012;7; e33865.
- [8] Knecht H, Neulinger SC, Heinsen FA, Knecht C, Schilhabel A, Schmitz RA, et al. Effects of beta-lactam antibiotics and fluoroquinolones on human gut microbiota in relation to *Clostridium difficile* associated diarrhea. *PloS one*. 2014;9; e89417.
- [9] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19; 210-216.
- [10] Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Applied Psychological Measurement*. 1977;1; 385-401.
- [11] Nast A, Jacobs A, Rosumeck S, Werner RN. Methods Report: European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol*. 2015;29; e1-22.
- [12] Nestle FO, Kaplan DH, Barker J. Mechanism of Disease: Psoriasis. *New England Journal of Medicine*. 2009;361; 496-509.
- [13] Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, et al. Community differentiation of the cutaneous microbiota in psoriasis. *Microbiome*. 2013;1; 31.

- [14] von Rosenvinge EC, Song Y, White JR, Maddox C, Blanchard T, Fricke WF. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. *The ISME journal*. 2013.
- [15] Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. *Microbiome*. 2018;6; 226.
- [16] Kong HH, Andersson B, Clavel T, Common JE, Jackson SA, Olson ND, et al. Performing Skin Microbiome Research: A Method to the Madness. *The Journal of investigative dermatology*. 2017.
- [17] Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq Illumina sequencing platform. *Applied and environmental microbiology*. 2013;79; 5112-5120.
- [18] Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic acids research*. 2013;41; D590-596.
- [19] Team RC. R: A language and environment for statistical computing. 3.6.2 ed. Vienna, Austria. R Foundation for Statistical Computing, 2020.
- [20] McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PloS one*. 2013;8; e61217.
- [21] Knight R, Vrbanac A, Taylor BC, Aksenov A, Callewaert C, Debelius J, et al. Best practices for analysing microbiomes. *Nature reviews Microbiology*. 2018;16; 410-422.
- [22] StataCorp LP. Stata Statistical Software: Release 13. 13.1 ed. College Station, TX, 2013.
- [23] Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, USA. Springer-Verlag. 2009.
- [24] Oksanen J, Guillaume B, Friendly M, Kindt R, Legendre P, McGlinn D, et al. vegan: Community Ecology Package. R package version 2.5-6., 2019.
- [25] Magurran AE, McGill BJ. Biodiversity: frontiers in measurement and assessment. United States. Oxford University Press. 2011.
- [26] Anderson MJ. Distance-based tests for homogeneity of multivariate dispersions. *Biometrics*. 2006;62; 245-253.
- [27] Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. *Nature reviews Microbiology*. 2018;16; 143-155.

- [28] Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. *JAMA : the journal of the American Medical Association*. 2011;306; 2331-2339.
- [29] Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM. Serious infections among a large cohort of subjects with systemically treated psoriasis. *J Am Acad Dermatol*. 2017;77; 838-844.
- [30] Sanchez-Moya AI, Garcia-Doval I, Carretero G, Sanchez-Carazo J, Ferrandiz C, Herrera Ceballos E, et al. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. *J Eur Acad Dermatol Venereol*. 2013;27; 1366-1374.
- [31] Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. *J Am Acad Dermatol*. 2017;76; 299-308.e216.
- [32] Gómez-García F, Epstein D, Isla-Tejera B, Lorente A, Vélez García-Nieto A, Ruano J. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *The British journal of dermatology*. 2017;176; 594-603.
- [33] Fowler E, Ghamrawi RI, Ghiam N, Liao W, Wu JJ. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. *J Eur Acad Dermatol Venereol*. 2020;34; 1449-1456.
- [34] Tsuda K, Yamanaka K, Kondo M, Matsubara K, Sasaki R, Tomimoto H, et al. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity. *PloS one*. 2012;7; e51819.
- [35] Assarsson M, Duvetorp A, Dienus O, Soderman J, Seifert O. Significant Changes in the Skin Microbiome in Patients with Chronic Plaque Psoriasis after Treatment with Narrowband Ultraviolet B. *Acta dermato-venereologica*. 2018;98; 428-436.
- [36] Quan C, Chen XY, Li X, Xue F, Chen LH, Liu N, et al. Psoriatic lesions are characterized by higher bacterial load and imbalance between *Cutibacterium* and *Corynebacterium*. *J Am Acad Dermatol*. 2020;82; 955-961.
- [37] Fahlen A, Engstrand L, Baker BS, Powles A, Fry L. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. *Arch Dermatol Res*. 2012;304; 15-22.
- [38] Rausch P, Basic M, Batra A, Bischoff SC, Blaut M, Clavel T, et al. Analysis of factors contributing to variation in the C57BL/6J fecal microbiota across German animal facilities. *International journal of medical microbiology : IJMM*. 2016;306; 343-355.

[39] Twomey KB, Alston M, An SQ, O'Connell OJ, McCarthy Y, Swarbreck D, et al. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. *PloS one*. 2013;8; e82432.

[40] Hagg D, Sundstrom A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. *Am J Clin Dermatol*. 2017;18; 583-590.

[41] Chen Y, Knight R, Gallo RL. Evolving approaches to profiling the microbiome in skin disease. *Front Immunol*. 2023 Apr 4;14:1151527. doi: 10.3389/fimmu.2023.1151527.

1 **Figure Legends**

2 **Fig 1a.** Alpha diversity measures for quantifying within-sample microbial richness (OTU,
3 Chao1), diversity (Shannon D), and compositional evenness (Shannon E) in samples from
4 healthy controls and psoriasis patients in the 3 therapeutic classes. Over the study period,
5 significant differences included a relative decrease and increase in Shannon D and Shannon E in
6 samples associated with TNF- α Inhibitor and nonbiologics as compared to anti-ILAb (adjusted
7 P<0.01).

8

9 **Fig 1b.** Principal coordinates analysis of genus-level community data from patients of different
10 therapeutic class. Based on 10^4 permutations, pairwise comparisons of distances between group
11 centroids (solid circles) revealed significant community dissimilarities between TNF- α Inhibitor
12 and anti-ILAb patients (P <0.001) or nonbiologics patients (P < 0.001) as well as between non-
13 biologics and anti-ILAb users (P <0.01).

14 **Fig 2.** Boxplots of selected hTRB-V and -J segments with significant differential usage in
15 peripheral CD3+ T-cells between skin-healthy controls and psoriasis patients at baseline (T0)
16 and those at 12-15 weeks after anti-IL4 treatment began (T2). Normalized usage was the
17 proportion of each segment being identified in all CDR3 clonotypes of a given sample; the copy
18 number of each clonotype was not taken into account in order to avoid the influence of clonal
19 expansion on estimating sample-specific segment usage. Usage of segment hTRBJ1-2
20 (difference: 2.2%, 95%CI: 1.8%, 2.6%) and hTRBV9 (difference: 4.3%, 95%CI: 1.0%, 7.6%)
21 were significantly higher in healthy controls than in psoriasis patients before treatment. In
22 contrast, the normalized usage of hTRBJ2-7 (difference: 11.5%, 95%CI: 2.1%, 20.9%),
23 hTRBV11-2 (difference: 1.5%, 95%CI: 1.1%, 1.9%), and hTRBV27 (difference: 1.3%, 95%CI:
24 0.8%, 1.8%) were statistically higher in psoriasis patients than in controls. NS, non-significant; *:
25 $P < .05$; **: $P < .01$; ***: $P < .001$.

Table 1. Characteristics of psoriasis patients and skin-healthy control participants at baseline, 2015-2019

Characteristics, %	Psoriasis Patients			P-value ^a	Skin-healthy Controls	P-value ^b
	Non-biologics (N=6)	TNF- α Inhibitors (N=13)	Anti-ILAbs (N=42)		(N=29)	
Follow-up time (days), Median (IQR)	98 (77-112)	103 (94-119)	108 (84-112)	0.318	84 (84-91)	<0.001
Age (years), Median (IQR)	41 (37-44)	40 (32-58)	44 (35-52)	0.318	51 (45-58)	0.006
20-36	17%	46%	29%	0.189	3%	0.003
36-50	83%	23%	43%		45%	
\geq 50	0	31%	29%		52%	
Male	100%	92%	83%	0.587	62%	0.007
BMI (Kg/m ²), Median (IQR)	27.3 (26.8-33.0)	28.7 (26.3-30.7)	27.7 (25.9-29.7)	0.450	24.7 (23.1-26.2)	<0.001
WC (cm) ^c , Median (IQR)	96 (91-102)	97 (93-108)	92 (82-100)	0.240	79 (76-85)	<0.001
Education ^c						
Less than high school	0	23%	36%	0.183	17%	0.421
High or vocational school	43%	23%	38%		34%	
College or higher	57%	54%	26%		45%	
Disease duration (years), Median (IQR)	22 (20-36)	21 (20-33)	26 (19-33)	0.422	-	-
Treatment-naive	57%	23%	29%	0.546	-	-
Regular alcohol use	14%	23%	24%	0.545	21%	0.946
Regular smoking					N=28	
Never	29%	77%	55%	0.284	79%	0.040
Quitted	0	0	12%		10%	
Yes	71%	23%	33%		10%	
Regular use of antiseptics for						
Face ^d	14%	8%	2%	0.226	0	0.551
Hand ^e	0	15%	7%	0.755	7%	1.000
Staphylococcal colonization						
Lesion/ skin	57%	23%	31%	0.507	7%	0.015
Nares	43%	15%	19%	0.211	7%	0.130
Clinical Outcomes						
PASI, Median (IQR)	15 (14-20)	13 (11-17)	15 (11-24)	0.698 ^a	-	
DLQI, Median (IQR)	12 (8-22)	9 (4-14)	10 (3-15)	0.796 ^a	-	

CESD, Median (IQR)	17 (12-24)	13 (11-20)	16 (13-22)	0.431 ^a	13 (12-15)	0.059
--------------------	------------	------------	------------	--------------------	------------	-------

Abbreviations: BMI, body mass index; CESD, Center for Epidemiologic Studies Depression Scale; DLQI, Dermatology Life of Quality Index; anti-IL-Abs, anti-interleukin monoclonal antibodies; IQR, interquartile range; PASI, psoriasis area severity index; WC, waist circumference

- a. P-value for median test; Chi-square test, or Fisher's exact test among psoriasis patients using different treatment regimens
- b. P-value for median test; Chi-square test, or Fisher's exact test between psoriasis patients and control subjects
- c. One healthy control had missing data
- d. Three control subjects had missing data
- e. Three control and 1 psoriasis participants had missing data

Table 2. Differences in phylum-level relative abundance between lesional and healthy skin microbiota at baseline and during 12-15 weeks of systemic treatment in adult psoriasis patients overall, by sex and absence of prior treatment, 2016-2019^a

Relative Abundances (%)	Baseline (Cross-sectional model)		Baseline to 12-15 wk (Longitudinal model)	
	Unadjusted	Adjusted ^a	Unadjusted	Adjusted ^a
	beta (95%CI)	beta (95%CI)	beta (95%CI)	beta (95%CI)
Overall				
Proteobacteria	0.03 (-0.00, 0.06)	4.54 (0.33, 8.75) b	2.35 (0.58, 4.11)c	3.35 (1.44, 5.25)d
Firmicutes	-0.01 (-0.03, 0.02)	-0.11 (-2.09, 1.88)	-0.78 (2.14, 0.58)	-0.24 (-1.91, 1.42)
Actinobacteria	-0.01 (-0.02, -0.00) b	-1.15 (-2.73, 0.44)	-1.07 (-1.97, -0.18) b	-0.94 (-2.11, 0.23)
Bacteroidetes	-0.002 (-0.01, 0.01)	-0.55 (-2.20, 1.10)	-0.32 (-1.06, 0.43)	-0.15 (-1.49, 0.59)
Men				
Proteobacteria	4.28 (0.89, 7.67) b	5.30 (0.24, 10.4) b	2.66 (0.64, 4.68)c	4.13 (1.88, 6.38)d
Firmicutes	-1.12 (-3.90, 1.65)	0.04 (-2.13, 2.21)	-0.72 (-2.45, 1.01)	-0.97 (-2.43, 0.48)
Actinobacteria	-1.33 (-2.70, 0.04)	-0.88 (-2.71, 0.96)	-1.64 (-2.71, -0.57)c	-0.87 (-2.18, 0.45)
Bacteroidetes	-0.25 (-1.78, 1.29)	-0.49 (-2.33, 1.36)	-0.44 (-1.43, 0.55)	-0.19 (-1.46, 1.08)
Women				
Proteobacteria	0.97 (-5.71, 7.65)	-4.61 (-14.4, 5.19)	0.53 (-3.78, 4.85)	-0.64 (-6.77, 5.49)
Firmicutes	-0.08 (-5.81, 5.66)	5.08 (-5.54, 15.7)	-2.15 (-4.95, 0.64)	-0.23 (-3.99, 3.53)
Actinobacteria	-1.00 (-3.31, 1.32)	-0.88 (-4.47, 2.70)	-0.63 (-2.20, 0.93)	-0.97 (-2.82, 0.87)
Bacteroidetes	0.16 (-2.39, 2.70)	-0.10 (-4.08, 4.06)	0.16 (-1.15, 1.47)	-0.16 (-1.84, 1.53)
With prior treatment				
Proteobacteria	1.55 (-2.26, 5.36)	-0.12 (-5.69, 5.45)	3.41 (1.67, 5.15)d	2.37 (-0.34, 5.08)
Firmicutes	2.16 (0.29, 4.03) b	1.16 (-1.91, 4.24)	0.57 (-0.82, 1.96)	-0.22 (-2.07, 1.64)
Actinobacteria	-0.89 (-2.53, 0.74)	-2.03 (-3.92, -0.13) b	-0.98 (-2.50, 0.54)	-1.41 (-2.99, 0.16)
Bacteroidetes	1.32 (0.21, 2.42)	0.47 (-1.38, 2.32)	0.42 (-0.70, 1.54)	0.24 (-1.07, 1.56)
Without prior treatment				

Proteobacteria	4.45 (-0.14, 9.04)	4.64 (1.05, 8.22) ^c	3.39 (0.76, 6.03) ^b	3.45 (-0.02, 6.92)
Firmicutes	-7.38 (-10.6, -4.11)^d	0.00 (-4.96, 4.96)	-7.30 (-9.39, -5.21)^d	-0.04 (-3.40, 3.32)
Actinobacteria	0.87 (-1.05, 2.79)	-1.14 (-3.22, 0.93)	1.03 (-0.26, 2.33)	-1.79 (-3.59, 0.01)
Bacteroidetes	-0.95 (-3.39, 1.49)	-1.85 (-4.63, 0.93)	-0.03 (-1.24, 1.19)	-0.57 (-2.13, 0.98)

Abbreviations: beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient

a. Age-, sex-, absence of prior treatment, study year-adjusted in baseline models; follow-up duration was also accounted for in the longitudinal models; all comparisons excluded data from 2015-2016, during which no control subjects were enrolled

b. $P < 0.05$

c. $P \leq 0.01$

d. $P \leq 0.001$

Table 3. Adjusted associations between phylum-level relative abundances of lesional microbiota and therapeutic class or clinical outcome at baseline and over time in psoriasis patients, 2015-2019^a

Relative Abundance (%)	Therapeutic Class		Clinical Assessment
	TNF-a	Nonbiologics	Severity (PASI > 10)
Baseline	beta (95%CI)	beta (95%CI)	beta (95%CI)
Proteobacteria	-6.98 (-12.2, -1.73)^b	0.62 (-4.04, 5.28)	-1.48 (-4.23, 1.26)
Firmicutes	1.27 (-2.57, 5.11)	7.83 (4.26, 10.5)^d	0.93 (-1.49, 3.35)
Actinobacteria	-0.63 (-1.79, 0.52)	-0.53 (-1.52, 2.59)	-0.60 (-1.93, 0.72)
Bacteroidetes	0.46 (-2.45, 3.37)	-2.13 (-3.99, -0.27) ^c	-0.76 (-2.86, 1.34)
Baseline to 12-15 wk			Response (PASI 75)
Proteobacteria	-1.67 (-4.40, 1.06)	0.84 (-1.94, 3.62)	-1.08 (-3.51, 1.35)
Firmicutes	0.10 (-2.06, 2.26)	4.15 (0.79, 7.52) ^c	0.30 (-1.73, 2.32)
Actinobacteria	-0.73 (-1.50, 0.03)	0.65 (-0.73, 2.03)	-0.75 (-1.68, 0.19)
Bacteroidetes	0.13 (-1.45, 1.71)	-1.47 (-2.49, -0.45)^b	-0.50 (-1.68, 0.69)

Abbreviations: Anti-ILAbs, anti-interleukin monoclonal antibodies; beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient; PASI, psoriasis area severity index

a. Age-, sex-, absence of prior treatment, study year, and follow-up duration-adjusted quantile regression models; baseline PASI scores were also adjusted in evaluating associations with clinical responses; reference group was patients using anti-ILAbs in comparisons by therapeutic class

b. $P < 0.01$

c. $P < 0.05$

d. $P \leq 0.001$

Table 4. Adjusted associations between genus-level alpha-diversity measures of lesional microbiota and therapeutic class or clinical assessment in adult psoriasis patients based at baseline and longitudinally, 2015-2019^a

beta (95%CI)	Therapeutic Class		Clinical Assessment
	TNF-a Inhibitors	Nonbiologics	Severity (PASI > 10)
Baseline			
Observed OTU	4.4 (-7.9, 16.7)	-6.8 (-19.9, 6.4)	-1.0 (-11.0, 9.1)
Chao1	18.9 (-4.5, 42.3)	15.3 (-26.3, 56.9)	-13.9 (-30.0, 2.1)
Shannon D	-0.23 (-0.49, 0.03)	0.08 (-0.19, 0.36)	-0.07 (-0.19, 0.06)
Shannon E	-0.04 (-0.08, 0.01)	0.04 (0.01, 0.07)	-0.01 (-0.03, 0.02)
Baseline to 12-15 wk			Response (PASI 75)
Observed OTU	-3.8 (-10.6, 3.0)	-9.0 (-25.0, 7.0)	-6.8 (-14.0, 0.4)
Chao1	-10.2 (-28.0, 7.6)	-6.3 (-30.9, 18.3)	-15.1 (-27.0, -3.3) ^c
Shannon D	-0.21 (-0.37, -0.06)^b	0.09 (-0.04, 0.22)	-0.07 (-0.15, 0.003)
Shannon E	-0.02 (-0.04, 0.004)	0.03 (0.01, 0.06)^b	0.01 (-0.02, 0.03)


Abbreviations: Anti-ILAbs, anti-interleukin monoclonal antibodies; beta, beta coefficient estimate in median regression models; CI, confidence interval for beta coefficient; PASI, psoriasis area severity index; PASI 75, reduction of PASI at follow-up > 75% of baseline PASI; OTU, operational taxonomy unit; Shannon D, Shannon diversity index; Shannon E, Shannon evenness index

a. Age-, sex-, absence of prior treatment, study year-adjusted quantile regression models; baseline PASI scores were also adjusted in longitudinally evaluating associations with clinical responses; reference group was patients using anti-ILAbs in comparisons by therapeutic class

b. P < 0.01

c. P < 0.05

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

